BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro.

[1]  K. Yamaguchi,et al.  The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration , 2021, Gastric Cancer.

[2]  Tongyue Zhang,et al.  Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation , 2021, Theranostics.

[3]  K. Almhanna,et al.  Does tumor profile in gastric and gastroesophageal (GE) junction cancer justify off-label use of targeted therapy?—a narrative review , 2020, Annals of translational medicine.

[4]  S. Oesterreich,et al.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors. , 2020, Pharmacology & therapeutics.

[5]  Nicolas Stransky,et al.  First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma. , 2019, Cancer discovery.

[6]  Yoon-Koo Kang,et al.  Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. , 2019, Cancer discovery.

[7]  S. Pal,et al.  Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19-FGF4-KLB Pathway Inhibition. , 2019, Cancer discovery.

[8]  J. Beijnen,et al.  P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). , 2019, International journal of pharmaceutics.

[9]  P. Malfertheiner,et al.  Review: Gastric cancer—Clinical aspects , 2019, Helicobacter.

[10]  Sung‐Min Ahn,et al.  FGF19–FGFR4 Signaling in Hepatocellular Carcinoma , 2019, Cells.

[11]  Jun Yu,et al.  Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis , 2019, Cells.

[12]  R. Roskoski.  Targeting ERK1/2 protein-serine/threonine kinases in human cancers. , 2019, Pharmacological research.

[13]  J. Beijnen,et al.  Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. , 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[14]  J. Smaill,et al.  Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. , 2018, Journal of medicinal chemistry.

[15]  Qianming Chen,et al.  Role of fibroblast growth factor receptor 4 in cancer , 2018, Cancer science.

[16]  S. Cook,et al.  ERK1/2 inhibitors: New weapons to inhibit the RAS‐regulated RAF‐MEK1/2‐ERK1/2 pathway , 2018, Pharmacology & therapeutics.

[17]  N. Yee.  Update in Systemic and Targeted Therapies in Gastrointestinal Oncology , 2018, Biomedicines.

[18]  Yong Teng,et al.  FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling. , 2017, Cancer research.

[19]  Jurgen Müller,et al.  Negative feedback regulation of the ERK1/2 MAPK pathway , 2016, Cellular and Molecular Life Sciences.

[20]  Zujiang Yu,et al.  The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer , 2016, Tumor Biology.

[21]  Yanying Shen,et al.  Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer. , 2015, World journal of gastroenterology.

[22]  Ye Zhou,et al.  Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer. , 2013, Oncology reports.

[23]  C. Du,et al.  The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients , 2012, Journal of surgical oncology.

[24]  P. Marie,et al.  FGF/FGFR signaling in bone formation: Progress and perspectives , 2012, Growth factors.

[25]  C. Du,et al.  Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression , 2011, Cancer.